History of significant bleeding disorder unrelated to chronic myelogenous leukemia (CML), including:\r\n* Diagnosed congenital bleeding disorders (e.g. von Willebrand’s disease) \r\n* Diagnosed acquired bleeding disorder within one year (e.g. acquired anti-factor VII antibodies)
History of significant bleeding disorder unrelated to cancer, including:\r\n* Diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease)\r\n* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)\r\n* Ongoing or recent (=< 3 months) significant gastrointestinal bleeding
History of significant bleeding disorder unrelated to cancer, including: \r\n* Diagnosed congenital bleeding disorders (e.g., von Willebrand’s’ disease) \r\n* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies) \r\n* History of gastrointestinal (GI) bleeding within one year
History of significant bleeding disorder unrelated to cancer, including: 1) diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease); 2) diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies) of screening visit; 3) history of gastrointestinal (GI) bleeding within 3 months of screening visit requiring >= 2 units packed red blood cells.
History of significant bleeding disorder unrelated to cancer, including: diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease); diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies).
History of significant bleeding disorder unrelated to cancer, including: diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease, diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies, or ongoing or recent (=< 3 months) significant gastrointestinal bleeding
History of significant bleeding disorder unrelated to cancer, including: Diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease); and diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies).
No abnormalities no history of diagnosed acquired bleeding disorders within one year (e.g., acquired anti-factor VIII antibodies) of registration on protocol therapy
Patients meeting the following criteria are not eligible unless cleared by cardiology: \r\n* Uncontrolled angina within 3 months\r\n* Diagnosed or suspected congenital long QT syndrome\r\n* Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)\r\n* Prolonged corrected QT (QTc) interval on pre-entry electrocardiogram (> 460 msec) \r\n* History of significant bleeding disorder unrelated to cancer, including: \r\n** Diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease) \r\n** Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
History of significant bleeding disorder unrelated to cancer, including:\r\n* Diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease)\r\n* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
History of significant bleeding disorder unrelated to cancer, including:\r\n* Diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease)\r\n* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)\r\n* Ongoing or recent (=< 3 months) significant gastrointestinal bleeding
History of significant bleeding disorder unrelated to cancer, including diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease), or diagnosed acquired bleeding disorders within one year (e.g., acquired anti-factor VIII antibodies)
History of significant bleeding disorder unrelated to cancer, including:\r\n* Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)\r\n* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
History of significant bleeding disorder unrelated to cancer, including diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease)
History of significant bleeding disorder unrelated to cancer, including:\r\n* Diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease)\r\n* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
Known bleeding disorders with the exception of acquired Von Willebrand disorder suspected on the basis of WM
Concurrent medical conditions or injury which may increase the risk of toxicity, including ongoing or active infection, history of significant bleeding disorder unrelated to cancer (congenital bleeding disorders, acquired bleeding disorders within one year), history of human immunodeficiency virus (HIV)-positive, or active or chronic hepatitis C and/or B infection
Concurrent medical conditions which may increase the risk of toxicity, including ongoing or active infection, history of significant bleeding disorder unrelated to cancer (congenital bleeding disorders, acquired bleeding disorders within one year), human immunodeficiency virus (HIV)-positive
History of significant bleeding disorder unrelated to cancer, including: congenital bleeding disorders (e.g, von Willebrand's disease), acquired bleeding disorder within the past 12 months (e.g, acquired anti-factor VIII antibodies, including any ongoing or recent less than or equal to 3 months), significant gastrointestinal bleeding, or use of oral anticoagulant therapy
History of significant bleeding disorder unrelated to cancer, including:\r\n* Diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease)\r\n* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)\r\n* Ongoing or recent (=< 3 months) significant gastrointestinal bleeding
History of significant bleeding disorder unrelated to cancer, including: · Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease) · Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies) of Screening visit
History of significant bleeding disorder unrelated to cancer, including: diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease), diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
History of significant bleeding disorder unrelated to cancer, including:\r\n* Diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease)\r\n* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
Known inherited predisposition to bleeding or thrombosis
Known inherited predisposition to bleeding or thrombosis
Known inherited predisposition to bleeding or thrombosis
Known inherited predisposition to bleeding or thrombosis
Known inherited predisposition to bleeding or thrombosis
Known inherited predisposition to bleeding or thrombosis
Known inherited predisposition to bleeding or thrombosis
History of thrombosis due to a known inherited hypercoagulable state
Known inherited predisposition to bleeding or thrombosis
Inherited predisposition to bleeding or thrombosis
Known inherited predisposition to thrombosis
Known predisposition to bleeding
Any patient with a known or suspected inherited predisposition to cancer should be discussed with the study team prior to screening for eligibility\r\n* Patients with a known inherited or constitutional predisposition to transplant morbidities, including, but not limited to Fanconi anemia, Dyskeratosis Congenita, Shwachman-Diamond syndrome and Down syndrome will be excluded\r\n* Patients with known inherited or constitutional predisposition to non-hematologic cancers including, but not limited to Li-Fraumeni syndrome, BRCA1 and BRCA2 mutations will be excluded\r\n* Patients with an inherited predisposition to leukemia or otherwise hematologic malignancies that have not been associated with predisposition to transplant morbidities or non-hematologic cancers will not be excluded
For patient with known history or predisposition to cardiac abnormalities: in the Investigator's opinion the history/predisposition should not jeopardize patient's safety during the study.
Known bleeding disorders (e.g., von Willebrand’s disease) or hemophilia
Known bleeding disorders (e.g., von Willebrand’s disease) or hemophilia
The patient has a known predisposition for bleeding such as von Willebrand's disease or other such condition.
Known bleeding diathesis (eg, von Willebrand’s disease) or hemophilia
CRITERIA SPECIFIC FOR COHORT #2 (MCL): Known bleeding disorders (eg, von Willebrand's disease) or hemophilia
Evidence of bleeding diathesis or coagulopathy within 3 months (eg, von Willebrand’s disease or hemophilia.
Known bleeding disorders (e.g., von Willebrand’s disease or hemophilia)
Known bleeding disorders (eg, von Willebrand’s disease) or hemophilia
Known bleeding disorders (von Wilebrand’s disease or hemophilia)
Known predisposition for bleeding such as von Willebrand’s disease or other such condition(s)
Known bleeding disorders (e.g., von Willebrand’s disease) or hemophilia
Known bleeding disorders (eg, von Willebrand’s disease) or hemophilia
Known bleeding disorders (e.g., von Willebrand’s disease) or hemophilia
No history of diagnosed congenital bleeding disorders (e.g., von Willebrand’s disease)
Known bleeding disorders (e.g., von Willebrand's disease) or hemophilia
Known bleeding disorders (e.g., von Willebrand’s disease) or hemophilia
Known bleeding disorders (e.g., von Willebrand’s disease) or hemophilia
Known bleeding disorders (e.g., von Willebrand’s disease) or hemophilia
Known bleeding disorders (e.g., von Willebrand’s disease) or hemophilia
known bleeding disorders or hemophilia
Known bleeding disorders (e.g., von Willebrand’s disease) or hemophilia
Known bleeding disorders (eg, von Willebrand’s disease) or hemophilia
Known bleeding disorders (e.g., severe von Willebrand’s disease) or severe hemophilia
Patients with known bleeding diathesis (e.g. von Willebrand ‘s disease) or hemophilia
Known bleeding disorders (e.g., von Willebrand disease or hemophilia)
Known bleeding diathesis (e.g., von Willebrand’s disease) or hemophilia
Known bleeding disorders or hemophilia.
Known bleeding disorders (eg, von Willebrand's disease) or hemophilia.
Subjects with a bleeding diathesis (e.g., von Willebrand’s disease or hemophilia) are not eligible
Patient must not have any known bleeding disorders (e.g., von Willebrand’s disease) or hemophilia
Known bleeding disorders (e.g. von Willebrand’s disease) or hemophilia
Known bleeding disorders (e.g., von Willebrand’s disease) or hemophilia
Known history of bleeding diathesis or coagulopathy (e.g., von Willebrand disease or hemophilia)
Known history of bleeding disorders (e.g., von Willebrand disease or hemophilia).
Known bleeding diathesis (e.g., von Willebrand's disease) or hemophilia
Known congenital bleeding disorders such as hemophilia
Known bleeding disorders (e.g., von Willebrand's disease) or hemophilia.
History of bleeding diathesis or known qualitative platelet defect (including von Willebrand disease)
Known bleeding disorders (e.g., von Willebrand’s disease) or hemophilia
Known history of bleeding disorders, eg, von Willebrand disease or hemophilia
Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)
Disorders of hemostasis including von Willebrand disease, hemophilia, platelet function disorders
Known bleeding disorders (eg, von Willebrand’s disease or hemophilia), active bleeding disorders or clinical signs of bleeding (grade >= 2)
Known bleeding disorders (e.g., von Willebrand’s disease) or hemophilia
Patient has a known bleeding diathesis (e.g. von Willebrand’s disease) or hemophilia
EXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Known bleeding disorders (eg, von Willebrand’s disease) or hemophilia
Hemophilia
Patients with a documented history of coagulopathy such as hemophilia or von Willebrand’s disease or inherited thrombophilia
Hemophilia
Known bleeding disorders (e.g., von Willebrand’s disease) or hemophilia
The patient has a known predisposition for bleeding such as von Willebrand's disease or other such condition.
